CoChat
Sign Up
Cited by 64

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Insulin-like Growth Factor-1 and IGF Binding Proteins Predict All-Cause Mortality and Morbidity in Older Adults

Zhang, William B., Aleksic, Sandra, Gao, Tina, Weiss, Erica F., Demetriou, Eleni, Verghese, Joe, Holtzer, Roee, Barzilai, Nir, Milman, Sofiya·2020·Cells
DOI 10.3390/cells9061368PMC PMC7349399
Open this paper in CoChat — free account

Abstract

While the growth hormone/insulin-like growth factor-1 (GH/IGF-1) pathway plays essential roles in growth and development, diminished signaling via this pathway in model organisms extends lifespan and health-span. In humans, circulating IGF-1 and IGF-binding proteins 3 and 1 (IGFBP-3 and 1), surrogate measures of GH/IGF-1 system activity, have not been consistently associated with morbidity and mortality. In a prospective cohort of independently-living older adults (n = 840, mean age 76.1 ± 6.8 years, 54.5% female, median follow-up 6.9 years), we evaluated the age- and sex-adjusted hazards for all-cause mortality and incident age-related diseases, including cardiovascular disease, diabetes, cancer, and multiple-domain cognitive impairment (MDCI), as predicted by baseline total serum IGF-1, IGF-1/IGFBP-3 molar ratio, IGFBP-3, and IGFBP-1 levels. All-cause mortality was positively associated with IGF-1/IGFBP-3 molar ratio (HR 1.28, 95% CI 1.05–1.57) and negatively with IGFBP-3 (HR 0.82, 95% CI 0.680–0.998). High serum IGF-1 predicted greater risk for MDCI (HR 1.56, 95% CI 1.08–2.26) and composite incident morbidity (HR 1.242, 95% CI 1.004–1.538), whereas high IGFBP-1 predicted lower risk for diabetes (HR 0.50, 95% CI 0.29–0.88). In conclusion, higher IGF-1 levels and bioavailability predicted mortality and morbidity risk, supporting the hypothesis that diminished GH/IGF-1 signaling may contribute to human longevity and health-span.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells9061368

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Insulin-like growth factor (IGF)-associated proteins and mortality. Unadjusted survival curves for individuals with high and low levels of IGF-1 (a. combined cohort; b. males; c. females), IGFBP-1 (d–f), IGFBP-3 (g–i), and IGF-1/IGFBP-3 molar ratio (j–l).
Figure 1 Insulin-like growth factor (IGF)-associated proteins and mortality. Unadjusted survival curves for individuals with high and low levels of IGF-1 (a. combined cohort; b. males; c. females), IGFBP-1 (d–f), IGFBP-3 (g–i), and IGF-1/IGFBP-3 molar ratio (j–l).CC BY · PubMed Central
Figure 2 IGF-associated proteins and mortality hazard. Sex and age-adjusted survival hazards for combined cohort (a) and age-adjusted survival hazard for males (b) and females (c) with high levels of IGF-associated proteins as compared to individuals with low levels.
Figure 2 IGF-associated proteins and mortality hazard. Sex and age-adjusted survival hazards for combined cohort (a) and age-adjusted survival hazard for males (b) and females (c) with high levels of IGF-associated proteins as compared to individuals with low levels.CC BY · PubMed Central
Figure 3 IGF-1 levels and morbidity. Unadjusted survival curves for multiple-domain cognitive impairment (MDCI) (a. combined cohort; b. males; c. females), diabetes (d–f), cardiovascular disease (g–i), cancer (j–l), and composite incident morbidity (m–o) in individuals with high and low levels of IGF-1.
Figure 3 IGF-1 levels and morbidity. Unadjusted survival curves for multiple-domain cognitive impairment (MDCI) (a. combined cohort; b. males; c. females), diabetes (d–f), cardiovascular disease (g–i), cancer (j–l), and composite incident morbidity (m–o) in individuals with high and low levels of IGF-1.CC BY · PubMed Central
Figure 4 IGF-1 and morbidity hazard. Sex and age-adjusted morbidity hazards for all individuals in cohort (a), and age-adjusted morbidity hazards for males (b) and females (c) with high levels of IGF-1 as compared to individuals with low levels.
Figure 4 IGF-1 and morbidity hazard. Sex and age-adjusted morbidity hazards for all individuals in cohort (a), and age-adjusted morbidity hazards for males (b) and females (c) with high levels of IGF-1 as compared to individuals with low levels.CC BY · PubMed Central
Figure 5 IGFBP-1 levels and morbidity. Unadjusted survival curves for MDCI (a. combined cohort; b. males; c. females), diabetes (d–f), cardiovascular disease (g–i), cancer (j–l), and composite incident morbidity (m–o) in individuals with high and low levels of IGFBP-1.
Figure 5 IGFBP-1 levels and morbidity. Unadjusted survival curves for MDCI (a. combined cohort; b. males; c. females), diabetes (d–f), cardiovascular disease (g–i), cancer (j–l), and composite incident morbidity (m–o) in individuals with high and low levels of IGFBP-1.CC BY · PubMed Central
Figure 6 IGFBP-1 and morbidity hazard. Sex and age-adjusted morbidity hazards for all individuals (a), and age-adjusted morbidity hazard for males (b) and females (c) with high levels of IGFBP-1 as compared to individuals with low levels.
Figure 6 IGFBP-1 and morbidity hazard. Sex and age-adjusted morbidity hazards for all individuals (a), and age-adjusted morbidity hazard for males (b) and females (c) with high levels of IGFBP-1 as compared to individuals with low levels.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 89

  1. Goldman, 2016, Preparing for an Aging World: Engaging Biogerontologists, Geriatricians, and the Society, J. Gerontol. A Biol. Sci. Med. Sci., 71, 435, 10.1093/gerona/glv164 · DOI
  2. Guarente, 2000, Genetic pathways that regulate ageing in model organisms, Nature, 408, 255, 10.1038/35041700 · DOI
  3. Sonntag, 2012, Diverse roles of growth hormone and insulin-like growth factor-1 in mammalian aging: Progress and controversies, J. Gerontol. A Biol. Sci. Med. Sci., 67, 587, 10.1093/gerona/gls115 · DOI
  4. Kenyon, 1993, A C. elegans mutant that lives twice as long as wild type, Nature, 366, 461, 10.1038/366461a0 · DOI · Paper page
  5. Broughton, 2005, Longer lifespan, altered metabolism, and stress resistance in Drosophila from ablation of cells making insulin-like ligands, Proc. Natl. Acad. Sci. USA, 102, 3105, 10.1073/pnas.0405775102 · DOI · Paper page
  6. Borg, 1996, Dwarf mice and the ageing process, Nature, 384, 33, 10.1038/384033a0 · DOI
  7. Ikeno, 2003, Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: Correlation to extended longevity, J. Gerontol. A Biol. Sci. Med. Sci., 58, 291, 10.1093/gerona/58.4.B291 · DOI
  8. Flurkey, 2001, Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production, Proc. Natl. Acad. Sci. USA, 98, 6736, 10.1073/pnas.111158898 · DOI · Paper page
  9. Coschigano, 2000, Assessment of growth parameters and life span of GHR/BP gene-disrupted mice, Endocrinology, 141, 2608, 10.1210/endo.141.7.7586 · DOI · Paper page
  10. Kinney, 2001, Evidence that Ames dwarf mice age differently from their normal siblings in behavioral and learning and memory parameters, Horm. Behav., 39, 277, 10.1006/hbeh.2001.1654 · DOI
  11. Ikeno, 2009, Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice, J. Gerontol. A Biol. Sci. Med. Sci., 64, 522, 10.1093/gerona/glp017 · DOI
  12. Spadaro, 2016, Growth Hormone Receptor Deficiency Protects against Age-Related NLRP3 Inflammasome Activation and Immune Senescence, Cell Rep., 14, 1571, 10.1016/j.celrep.2016.01.044 · DOI
  13. Wolf, 1993, Effects of long-term elevated serum levels of growth hormone on life expectancy of mice: Lessons from transgenic animal models, Mech. Ageing Dev., 68, 71, 10.1016/0047-6374(93)90141-D · DOI
  14. Bartke, 2002, Consequences of growth hormone (GH) overexpression and GH resistance, Neuropeptides, 36, 201, 10.1054/npep.2002.0889 · DOI
  15. Balasubramanian, 2011, Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans, Sci. Transl. Med., 3, 70ra13
  16. Colao, 2004, Systemic complications of acromegaly: Epidemiology, pathogenesis, and management, Endocr. Rev., 25, 102, 10.1210/er.2002-0022 · DOI
  17. Dal, 2018, Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature, J. Clin. Endocrinol. Metab., 103, 2182, 10.1210/jc.2017-02457 · DOI
  18. Dekkers, 2008, Mortality in acromegaly: A metaanalysis, J. Clin. Endocrinol. Metab., 93, 61, 10.1210/jc.2007-1191 · DOI
  19. Friedrich, 2014, Age- and Sex-Specific Reference Intervals Across Life Span for Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 Ratio Measured by New Automated Chemiluminescence Assays, J. Clin. Endocrinol. Metab., 99, 1675, 10.1210/jc.2013-3060 · DOI
  20. Milman, 2014, Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity, Aging Cell, 13, 769, 10.1111/acel.12213 · DOI
  21. Rozing, 2015, Association analysis of insulin-like growth factor-1 axis parameters with survival and functional status in nonagenarians of the Leiden Longevity Study, Aging (Albany Ny), 7, 956
  22. Schutte, 2016, Attenuated IGF-1 predicts all-cause and cardiovascular mortality in a Black population: A five-year prospective study, Eur. J. Prev. Cardiol., 23, 1690, 10.1177/2047487316661436 · DOI
  23. Bourron, 2015, Impact of age-adjusted insulin-like growth factor 1 on major cardiovascular events after acute myocardial infarction: Results from the fast-MI registry, J. Clin. Endocrinol. Metab., 100, 1879, 10.1210/jc.2014-3968 · DOI
  24. Kaplan, 2008, Total insulinlike growth factor 1 and insulinlike growth factor binding protein levels, functional status, and mortality in older adults, J. Am. Geriatr Soc., 56, 652, 10.1111/j.1532-5415.2007.01637.x · DOI
  25. Juul, 2002, Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: A population-based case-control study, Circulation, 106, 939, 10.1161/01.CIR.0000027563.44593.CC · DOI · Paper page
  26. Saber, 2017, Serum Insulin-Like Growth Factor 1 and the Risk of Ischemic Stroke: The Framingham Study, Stroke A J. Cereb. Circ., 48, 1760, 10.1161/STROKEAHA.116.016563 · DOI
  27. Renehan, 2004, Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis, Lancet, 363, 1346, 10.1016/S0140-6736(04)16044-3 · DOI · Paper page
  28. Kaplan, 2007, Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke, J. Clin. Endocrinol. Metab., 92, 1319, 10.1210/jc.2006-1631 · DOI
  29. Ross, 1991, Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I, Clin. Endocrinol., 35, 47, 10.1111/j.1365-2265.1991.tb03495.x · DOI
  30. Juul, 2003, Serum levels of insulin-like growth factor I and its binding proteins in health and disease, Growth Horm. Igf. Res., 13, 113, 10.1016/S1096-6374(03)00038-8 · DOI
  31. Friedrich, 2009, Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations, J. Clin. Endocrinol. Metab., 94, 1732, 10.1210/jc.2008-2138 · DOI
  32. Feldman, 2009, Unraveling insulin-like growth factor binding protein-3 actions in human disease, Endocr. Rev., 30, 417, 10.1210/er.2008-0028 · DOI
  33. Allard, 2018, IGF-Binding Proteins: Why Do They Exist and Why Are There So Many?, Front. Endocrinol. (Lausanne), 9, 117, 10.3389/fendo.2018.00117 · DOI
  34. Faix, 2013, Principles and pitfalls of free hormone measurements, Best Pract. Res. Clin. Endocrinol. Metab., 27, 631, 10.1016/j.beem.2013.06.007 · DOI
  35. Yeap, 2011, Associations of IGF1 and IGFBPs 1 and 3 with all-cause and cardiovascular mortality in older men: The Health In Men Study, Eur. J. Endocrinol. Eur. Fed. Endocr. Soc., 164, 715, 10.1530/EJE-11-0059 · DOI
  36. Gubbi, 2017, Effect of Exceptional Parental Longevity and Lifestyle Factors on Prevalence of Cardiovascular Disease in Offspring, Am. J. Cardiol., 120, 2170, 10.1016/j.amjcard.2017.08.040 · DOI
  37. Perice, 2016, Lower circulating insulin-like growth factor-I is associated with better cognition in females with exceptional longevity without compromise to muscle mass and function, Aging (Albany Ny), 8, 2414, 10.18632/aging.101063 · DOI
  38. The UniProt Consortium (2019). UniProt: A worldwide hub of protein knowledge. Nucleic Acids Res., 47, D506–D515. · DOI · Paper page
  39. Rinderknecht, 1978, The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin, J. Biol. Chem., 253, 2769, 10.1016/S0021-9258(17)40889-1 · DOI
  40. Johnson, 2014, CDC National Health Report: Leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005–2013, MMWR Suppl., 63, 3
  41. Tabert, 2006, Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment, Arch. Gen. Psychiatry, 63, 916, 10.1001/archpsyc.63.8.916 · DOI
  42. Jak, 2009, Quantification of five neuropsychological approaches to defining mild cognitive impairment, Am. J. Geriatr. Psychiatry, 17, 368, 10.1097/JGP.0b013e31819431d5 · DOI · Paper page
  43. MacNee, 2014, Ageing and the border between health and disease, Eur. Respir. J., 44, 1332, 10.1183/09031936.00134014 · DOI
  44. Andreassen, 2009, IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population, Eur. J. Endocrinol. Eur. Fed. Endocr. Soc., 160, 25, 10.1530/EJE-08-0452 · DOI
  45. Bartke, 2017, GH and ageing: Pitfalls and new insights, Best Pract. Res. Clin. Endocrinol. Metab., 31, 113, 10.1016/j.beem.2017.02.005 · DOI
  46. Beekman, 2005, Reduced insulin/IGF-1 signalling and human longevity, Aging Cell, 4, 79, 10.1111/j.1474-9728.2005.00148.x · DOI
  47. Pawlikowska, 2009, Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity, Aging Cell, 8, 460, 10.1111/j.1474-9726.2009.00493.x · DOI
  48. Burgers, 2011, Meta-analysis and dose-response metaregression: Circulating insulin-like growth factor I (IGF-I) and mortality, J. Clin. Endocrinol. Metab., 96, 2912, 10.1210/jc.2011-1377 · DOI
  49. Yamamoto, 1991, Effects of aging and sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults, Acta Endocrinol., 124, 497
  50. Gubbi, 2018, 40 YEARS of IGF1: IGF1: The Jekyll and Hyde of the aging brain, J. Mol. Endocrinol., 61, T171, 10.1530/JME-18-0093 · DOI
  51. 2009, Insulinlike growth factor-1, insulinlike growth factor binding protein-1, and cognitive function in older men and women, J. Am. Geriatr. Soc., 57, 1441, 10.1111/j.1532-5415.2009.02343.x · DOI
  52. Wennberg, 2018, The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging, Neurobiol. Aging., 66, 68, 10.1016/j.neurobiolaging.2017.11.017 · DOI
  53. Tumati, S., Burger, H., Martens, S., van der Schouw, Y.T., and Aleman, A. (2016). Association between Cognition and Serum Insulin-Like Growth Factor-1 in Middle-Aged & Older Men: An 8 Year Follow-Up Study. PLoS ONE, 11. · DOI
  54. Okereke, 2007, Plasma IGF-I levels and cognitive performance in older women, Neurobiol. Aging, 28, 135, 10.1016/j.neurobiolaging.2005.10.012 · DOI
  55. Liang, 2007, IGF-1 stimulates de novo fatty acid biosynthesis by Schwann cells during myelination, Glia, 55, 632, 10.1002/glia.20496 · DOI
  56. Defterali, 2016, IGF-I: A Key Growth Factor that Regulates Neurogenesis and Synaptogenesis from Embryonic to Adult Stages of the Brain, Front. Neurosci., 10, 52
  57. Gontier, 2015, Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer’s Disease Pathology through Amyloid-beta Clearance, J. Neurosci., 35, 11500, 10.1523/JNEUROSCI.0343-15.2015 · DOI
  58. Sevigny, 2008, Growth hormone secretagogue MK-677: No clinical effect on AD progression in a randomized trial, Neurology, 71, 1702, 10.1212/01.wnl.0000335163.88054.e7 · DOI
  59. Friedlander, 2001, One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women, J. Clin. Endocrinol. Metab., 86, 1496
  60. Schedlich, 2000, Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit, J. Biol. Chem., 275, 23462, 10.1074/jbc.M002208200 · DOI
  61. Schedlich, 2004, Insulin-like growth factor binding protein-3 prevents retinoid receptor heterodimerization: Implications for retinoic acid-sensitivity in human breast cancer cells, Biochem. Biophys. Res. Commun., 314, 83, 10.1016/j.bbrc.2003.12.049 · DOI
  62. Huang, 2003, Cellular growth inhibition by IGFBP-3 and TGF-beta1 requires LRP-1, FASEB J., 17, 2068, 10.1096/fj.03-0256com · DOI
  63. Cohen, 1993, Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth, Mol. Endocrinol., 7, 380
  64. Valentinis, 1995, The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene, Mol. Endocrinol., 9, 361
  65. Martin, 2003, Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. Involvement of p44/42 and p38 mitogen-activated protein kinases, J. Biol. Chem., 278, 2969, 10.1074/jbc.M210739200 · DOI
  66. Lofqvist, 2007, IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth, Proc. Natl. Acad. Sci. USA, 104, 10589, 10.1073/pnas.0702031104 · DOI
  67. Rajpathak, 2012, Insulin-like growth factor axis and risk of type 2 diabetes in women, Diabetes, 61, 2248, 10.2337/db11-1488 · DOI
  68. Petersson, 2009, Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): The Soderakra Cardiovascular Risk Factor Study, Diabetes Metab., 35, 198, 10.1016/j.diabet.2008.11.003 · DOI
  69. Lewitt, 2008, Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men, Diabetologia, 51, 1135, 10.1007/s00125-008-1016-x · DOI
  70. Suikkari, 1988, Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein, J. Clin. Endocrinol. Metab., 66, 266, 10.1210/jcem-66-2-266 · DOI
  71. Snyder, 1990, Insulin-dependent regulation of insulin-like growth factor-binding protein-1, J. Clin. Endocrinol. Metab., 71, 1632, 10.1210/jcem-71-6-1632 · DOI
  72. Clemmons, 2018, Role of IGF-binding proteins in regulating IGF responses to changes in metabolism, J. Mol. Endocrinol., 61, T139, 10.1530/JME-18-0016 · DOI
  73. Siddals, 2002, IGF-binding protein-1 inhibits IGF effects on adipocyte function: Implications for insulin-like actions at the adipocyte, J. Endocrinol., 174, 289, 10.1677/joe.0.1740289 · DOI
  74. Rajkumar, 1999, Impaired adipogenesis in insulin-like growth factor binding protein-1 transgenic mice, J. Endocrinol., 162, 457, 10.1677/joe.0.1620457 · DOI
  75. Haywood, 2017, Insulin-Like Growth Factor Binding Protein 1 Could Improve Glucose Regulation and Insulin Sensitivity Through Its RGD Domain, Diabetes, 66, 287, 10.2337/db16-0997 · DOI
  76. Wheatcroft, 2009, IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: Implications for metabolic homeostasis, Trends Endocrinol. Metab., 20, 153, 10.1016/j.tem.2009.01.002 · DOI
  77. Heald, 2001, Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations, Diabetologia, 44, 333, 10.1007/s001250051623 · DOI
  78. Unden, 2005, Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: A population-based study, Clin. Endocrinol., 63, 94, 10.1111/j.1365-2265.2005.02306.x · DOI
  79. Span, 2001, Gender differences in rhGH-induced changes in body composition in GH-deficient adults, J. Clin. Endocrinol. Metab., 86, 4161, 10.1210/jcem.86.9.7815 · DOI
  80. Frystyk, 2004, Free insulin-like growth factors -- measurements and relationships to growth hormone secretion and glucose homeostasis, Growth Horm. IGF Res., 14, 337, 10.1016/j.ghir.2004.06.001 · DOI
  81. Drogan, 2016, Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3 in Relation to the Risk of Type 2 Diabetes Mellitus: Results From the EPIC-Potsdam Study, Am. J. Epidemiol., 183, 553, 10.1093/aje/kwv188 · DOI
  82. Somers, 2009, IGF-I/IGFBP-3 ratio: A mechanistic insight into the metabolic syndrome, Clin. Sci., 116, 507, 10.1042/CS20080382 · DOI
  83. Gao, 2012, Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma, Int. J. Cancer, 131, E105, 10.1002/ijc.26438 · DOI
  84. Marzullo, 2001, Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults, J. Clin. Endocrinol. Metab., 86, 3001
  85. Soubry, 2012, Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps, Int. J. Cancer, 131, 512, 10.1002/ijc.26393 · DOI
  86. Cheng, 2010, Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer, Int. J. Cancer, 127, 568, 10.1002/ijc.25086 · DOI
  87. Mao, 2018, Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice, Nat. Commun., 9, 2394, 10.1038/s41467-018-04805-5 · DOI · Paper page
  88. Kopchick, 2006, Growth hormone receptor antagonists, Neuroendocrinology, 83, 264, 10.1159/000095537 · DOI
  89. Douglas, 2020, Teprotumumab for the Treatment of Active Thyroid Eye Disease, N. Engl. J. Med., 382, 341, 10.1056/NEJMoa1910434 · DOI

Cited by

Sorted by citations

See all 64

Metadata

Authors
Zhang, W. B., Aleksic, S., Gao, T., Weiss, E. F., Demetriou, E., Verghese, J., Holtzer, R., Barzilai, N., & Milman, S.
Affiliations
  • Department of Medicine, Division of Endocrinology, Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY 10461, USA
  • Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
  • Ferkauf Graduate School of Psychology, Yeshiva University, New York, NY 10033, USA
ORCID
Venue
Cells
Publisher
MDPI AG
Published
2020-06-01
Volume
9
Issue
6
Pages
1368
ISSN
2073-4409
DOI
10.3390/cells9061368
PMC
PMC7349399
Cited by
64
References
7
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • National Institute on Aging (K23AG051148, R01AG061155, P30AG038072, R01AG057909, R01AG044829-01A1, R01AG050448, T32AG023475-18)
  • National Institute of Neurological Disorders and Stroke (2R37NS43209, 1UG3NS105565–01, R01NS109023)
  • National Center for Advancing Translational Sciences (Einstein/Montefiore CTSA UL1TR002556)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review